Of note, the sensitivity of CLL cells to BCL‐2 inhibitors shown in these figures is consistent with previous reports.40 These data suggest that CLL cells are highly sensitive to CUDC‐907 at concentrations that are within the expected therapeutic levels that can be achieved in vivo, which range from 27 to 70 ng/mL.29, 30. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.